Der Börsen-Tag: Astrazeneca erleidet mit Krebsmedikament Rückschlag

The Börsen Tag
Astrazeneca is led by Krebsmedikament backstroke

23.09.2024, 13:06

That Krebs medicine Datopotamab Deruxtecan by AstraZeneca in a phase 3 trial, the research is not completed, so it can happen that the US Food and Drug Administration gets into trouble. The pharmaceutical industry consists of the experimental drug and more than 700 tested patients, who with an endogenous therapy and mental testing can develop a systemic therapy.

The results of the phase 3 study have no statistical significance in the final analysis of patients in the study with active standard of care, chemotherapy, i.e. Astrazeneca.